COMPANY PROFILE / #929
Aspen Neuroscience
Developer of autologous cell therapies and personalized medicines designed for a broad spectrum of diseases, starting with Parkinson's disease. The company's platform reprograms a patient's own cells into iPSC-derived neuronal precursors, incorporates automation, machine-learning-based quality control, and robotics-driven manufacturing, and places the resulting cells directly into targeted brain regions without immunosuppression, enabling the neurology market to access personalized therapeutic options aimed at restoring dopamine-related function.Privately Held (backing)
已融资123
最新估值—
员工数—
成立年份Anchor Therapeutics, Cerecin, Quince Therapeutics, Voyager Therapeutics, Valerion, Minoryx, BlueRock Therapeutics, Aro Biotherapeutics, Mitobridge, Homology Medicines, Cadent Therapeutics, Renova Therapeutics, ARMO BioSciences, QurAlis, ICBI, Rodin Therapeutics, Alzheon, Mighty Therapeutics, Brainstorm Cell Therapeutics, Numerion Labs, Forum Pharmaceuticals, Cognition Therapeutics, Verge Analytics, BPS Bioscience, Auspex Pharmaceuticals, Dimension Therapeutics, Fauna Bio, NGM Biopharmaceuticals, Tetra Therapeutics, T3D Therapeutics, Numerate, Travecta Therapeutics, Tiburio Therapeutics, Proclara Biosciences, Lisata Therapeutics, Intellia Therapeutics, Metabolic Solutions Development Company, Lysosomal Therapeutics, Cantabio Pharmaceuticals, Capricor Therapeutics, Akelos, Amicus Therapeutics, Fate Therapeutics, Spark Therapeutics, Aptuit, Nomad Power Solutions, Audentes Therapeutics, Sarepta Therapeutics, Gismo Therapeutics, NeuroNascent, Omeros, Compass Therapeutics, Vertex Pharmaceuticals, Alector, MedDay Pharmaceuticals, Minerva Neurosciences, ALSP, Bioasis Technologies, Medeia Therapeutics, Transition Therapeutics, Cerevel Therapeutics, uniQure, SAGE Therapeutics, ProMIS Neurosciences, Alnylam Pharmaceuticals, Recombinetics, Genetix Biotherapeutics, Design Therapeutics, Regulus Therapeutics, Bellus Health, PhotoPharmics, Arrowhead Pharmaceuticals, Athenex, ACADIA Pharmaceuticals, vTv Therapeutics, Moderna, Axsome Therapeutics, Cyclica, Prevail Therapeutics, SANA( Distributors/Wholesale)
公司概况
- Companies
- Aspen Neuroscience
- Description
- —
- Website
- San Diego, CA
- HQ Location
- Developer of autologous cell therapies and personalized medicines designed for a broad spectrum of diseases, starting with Parkinson's disease. The company's platform reprograms a patient's own cells into iPSC-derived neuronal precursors, incorporates automation, machine-learning-based quality control, and robotics-driven manufacturing, and places the resulting cells directly into targeted brain regions without immunosuppression, enabling the neurology market to access personalized therapeutic options aimed at restoring dopamine-related function.
- Year Founded
- Anchor Therapeutics, Cerecin, Quince Therapeutics, Voyager Therapeutics, Valerion, Minoryx, BlueRock Therapeutics, Aro Biotherapeutics, Mitobridge, Homology Medicines, Cadent Therapeutics, Renova Therapeutics, ARMO BioSciences, QurAlis, ICBI, Rodin Therapeutics, Alzheon, Mighty Therapeutics, Brainstorm Cell Therapeutics, Numerion Labs, Forum Pharmaceuticals, Cognition Therapeutics, Verge Analytics, BPS Bioscience, Auspex Pharmaceuticals, Dimension Therapeutics, Fauna Bio, NGM Biopharmaceuticals, Tetra Therapeutics, T3D Therapeutics, Numerate, Travecta Therapeutics, Tiburio Therapeutics, Proclara Biosciences, Lisata Therapeutics, Intellia Therapeutics, Metabolic Solutions Development Company, Lysosomal Therapeutics, Cantabio Pharmaceuticals, Capricor Therapeutics, Akelos, Amicus Therapeutics, Fate Therapeutics, Spark Therapeutics, Aptuit, Nomad Power Solutions, Audentes Therapeutics, Sarepta Therapeutics, Gismo Therapeutics, NeuroNascent, Omeros, Compass Therapeutics, Vertex Pharmaceuticals, Alector, MedDay Pharmaceuticals, Minerva Neurosciences, ALSP, Bioasis Technologies, Medeia Therapeutics, Transition Therapeutics, Cerevel Therapeutics, uniQure, SAGE Therapeutics, ProMIS Neurosciences, Alnylam Pharmaceuticals, Recombinetics, Genetix Biotherapeutics, Design Therapeutics, Regulus Therapeutics, Bellus Health, PhotoPharmics, Arrowhead Pharmaceuticals, Athenex, ACADIA Pharmaceuticals, vTv Therapeutics, Moderna, Axsome Therapeutics, Cyclica, Prevail Therapeutics, SANA( Distributors/Wholesale)
- Keywords
- 2025: 123, 2024: 111, 2023: 100, 2022: 52, 2021: 42, 2020: 21
- Competitors
- —
- Ownership Status
- —
- Company Financing Status
- Privately Held (backing)
融资与估值
- Total Raised
- 123
- First Financing Date
- 10.50
- First Financing Size
- 97
- First Financing Valuation
- cpeterson@gossamerbio.com
- Last Financing Date
- 0.87%
- Last Financing Deal Type
- 30-Sep-2025
- Last Financing Size
- Later Stage VC
- Last Financing Valuation
- —
- Last Financing Status
- 346.00
- Last Known Valuation
- —
- Last Known Valuation Date
- Later Stage VC
- Last Known Valuation Deal Type
- 4.50
- Valuation Estimate
- 30-Sep-2025
- Valuation Estimate Growth Rate
- autologous cell therapy, cell therapy, gene editing, gene therapy, neurological therapy, regenerative medicine development, stem cell therapy
- Active Investors
- Venture Capital-Backed
- # Active Investors
- 52%
- Acquirers
- Alexandria Venture Investments, ARCH Venture Partners, Axon Ventures, Balyasny Asset Management, California Institute for Regenerative Medicine, Cormorant Asset Management, Domain Associates, EDBI, Frazier Healthcare Partners, Frazier Lifesciences Acquisition, Gaingels, GV, Kite Pharma, Lifeforce Capital, LYFE Capital, Medical Excellence Capital, Mirae Asset Capital, Newton Investment Management, OrbiMed, Paratus Investment, Prebys Ventures, Quain Investments, Revelation Partners, S32, Samuel Altman, Timefolio Capital
团队与联系人
- Employees
- —
- Employee Growth %
- 2018
- Employee History
- —
- Primary Contact
- 379.30
- Primary Contact Title
- —
- Primary Contact Email
- Caryn Peterson
- Primary Contact Phone
- —
增长与经营
- Revenue
- —
- Revenue Growth %
- 37.46%
- Growth Rate
- —
- Growth Rate % Change
- —
- Growth Rate Percentile
- 210
- Size Multiple
- —
- Size Multiple % Change
- 346.00
- Size Multiple Change
- 0.00%
- Size Multiple Percentile
- 0.00x
- Majestic Referring Domains
- 8.08x
- SimilarWeb Unique Visitors
- —
- SimilarWeb Unique Visitors Change
- 30-Oct-2018
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 69%
- Success Probability Over Time – 3 Year
- 78%
- Success Probability Over Time – 5 Year
- Board Member
记录来源：public.companies · 原始序号 #929 · 所有字段均按数据库原值展示。